Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
BIO 
Bio-Rad Laboratories Inc (BIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: BIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $348
1 Year Target Price $348
| 2 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.89% | Avg. Invested days 44 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.54B USD | Price to earnings Ratio - | 1Y Target Price 348 |
Price to earnings Ratio - | 1Y Target Price 348 | ||
Volume (30-day avg) 6 | Beta 0.97 | 52 Weeks Range 211.43 - 387.99 | Updated Date 11/1/2025 |
52 Weeks Range 211.43 - 387.99 | Updated Date 11/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -24 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-30 | When After Market | Estimate 1.94 | Actual 2.26 |
Profitability
Profit Margin -26.43% | Operating Margin (TTM) 10.41% |
Management Effectiveness
Return on Assets (TTM) 1.57% | Return on Equity (TTM) -9.5% |
Valuation
Trailing PE - | Forward PE 32.79 | Enterprise Value 7948085078 | Price to Sales(TTM) 3.34 |
Enterprise Value 7948085078 | Price to Sales(TTM) 3.34 | ||
Enterprise Value to Revenue 3.11 | Enterprise Value to EBITDA 12.12 | Shares Outstanding 21906399 | Shares Floating 21119947 |
Shares Outstanding 21906399 | Shares Floating 21119947 | ||
Percent Insiders 16.28 | Percent Institutions 92.77 |
Upturn AI SWOT
Bio-Rad Laboratories Inc
Company Overview
History and Background
Bio-Rad Laboratories, Inc. was founded in 1952 in Berkeley, California. Initially focused on biochemical research, it expanded into clinical diagnostics and life science research products. Key milestones include the development of electrophoresis equipment and expansion into international markets. Over time, it grew through organic growth and strategic acquisitions.
Core Business Areas
- Life Science: Provides a wide range of instruments, reagents, and consumables for genomics, proteomics, cell biology, and bioprocessing applications. These products are used in academic, government, and industrial research settings.
- Clinical Diagnostics: Offers in vitro diagnostic products and systems used in clinical laboratories to detect, diagnose, and monitor diseases. These products include quality controls, diabetes testing, blood typing, and infectious disease testing.
Leadership and Structure
Norman Schwartz serves as Chairman and CEO. The organizational structure is divided into business units based on product lines and geographic regions. Key executives lead each business unit and report to the CEO.
Top Products and Market Share
Key Offerings
- Droplet Digital PCR (ddPCR): A highly precise method for nucleic acid quantification. Competitors include Thermo Fisher Scientific (TMO) and QIAGEN (QGEN). Market share data is difficult to pinpoint precisely, but Bio-Rad is considered a leader in this technology.
- Flow Cytometry: Instruments used for cell analysis and sorting. Key competitors include BD Biosciences (BDX) and Beckman Coulter (DHR). Bio-Rad holds a significant share in research flow cytometry.
- Quality Controls: A broad range of quality control products that test the accuracy of tests done in the clinical diagnostics market. A competitor is Roche (RHHBY). Bio-Rad is one of the leaders in this market.
Market Dynamics
Industry Overview
The life science and clinical diagnostics industries are driven by advancements in biotechnology, personalized medicine, and increasing healthcare spending. The market is highly competitive and regulated.
Positioning
Bio-Rad holds a strong position in both the life science and clinical diagnostics markets due to its innovative products, strong brand reputation, and global presence. Its competitive advantage lies in its breadth of product offerings and technological expertise.
Total Addressable Market (TAM)
The combined life science and clinical diagnostics market is expected to reach several hundred billion dollars. Bio-Rad is well-positioned to capture a significant share of this TAM through continued innovation and expansion.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Diverse product portfolio
- Global presence
- Innovative technologies
- Established customer base
Weaknesses
- Reliance on research and development
- Exposure to regulatory changes
- Vulnerability to economic downturns
- Dependence on third-party suppliers
Opportunities
- Expansion into emerging markets
- Development of new diagnostic tests
- Partnerships with pharmaceutical companies
- Increased adoption of personalized medicine
- Growing demand for bioprocessing solutions
Threats
- Intense competition
- Price pressure
- Technological obsolescence
- Intellectual property infringement
- Changes in healthcare regulations
Competitors and Market Share
Key Competitors
- TMO
- DHR
- RHHBY
Competitive Landscape
Bio-Rad competes with a range of large and specialized companies. Its strengths include its diverse product portfolio and strong brand reputation. Weaknesses include its reliance on R&D and exposure to regulatory changes.
Major Acquisitions
Exact Diagnostics
- Year: 2019
- Acquisition Price (USD millions): 145
- Strategic Rationale: Expanded Bio-Radu2019s quality controls portfolio and strengthened its position in the in vitro diagnostics market.
Growth Trajectory and Initiatives
Historical Growth: Bio-Rad has experienced moderate to strong growth over the past decade, driven by new product launches and strategic acquisitions.
Future Projections: Analysts project continued growth for Bio-Rad, driven by increasing demand for its products and services. Growth estimates vary depending on market conditions and company-specific factors.
Recent Initiatives: Recent initiatives include the expansion of its ddPCR product line, acquisitions of companies in related fields, and investments in R&D.
Summary
Bio-Rad Laboratories is a strong player in the life science and clinical diagnostics industries, supported by a diverse product portfolio and global presence. The company's innovation and strategic acquisitions have fueled growth. However, Bio-Rad faces intense competition and regulatory pressures, requiring continuous adaptation and efficiency improvements to maintain its market position. Their performance is healthy, but must watch for regulatory hurdles.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company filings (10-K reports)
- Analyst reports
- Industry publications
- Company Website
Disclaimers:
This analysis is based on available information and is not financial advice. Market conditions and company performance are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bio-Rad Laboratories Inc
Exchange NYSE | Headquaters Hercules, CA, United States | ||
IPO Launch date 1966-01-01 | Chairman & CEO Mr. Norman D. Schwartz | ||
Sector Healthcare | Industry Medical Devices | Full time employees 7700 | Website https://www.bio-rad.com |
Full time employees 7700 | Website https://www.bio-rad.com | ||
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials, such as cells, proteins, and nucleic acids used in biopharmaceutical manufacturing, quality control process, food safety, and science education applications. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, and transfusion and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.